Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2018, Article ID 5936360, 9 pages
https://doi.org/10.1155/2018/5936360
Research Article

Integration of Routine Parameters of Glycemic Variability in a Simple Screening Method for Partial Remission in Children with Type 1 Diabetes

1Pediatric Endocrinology Unit, Cliniques Universitaires Saint Luc, Av. Hippocrate 10, 1200 Brussels, Belgium
2Pôle Epidémiologie et Biostatistique, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Av. Hippocrate 10, 1200 Brussels, Belgium

Correspondence should be addressed to Philippe A. Lysy; eb.niavuolcu@ysyl.eppilihp

Received 8 October 2017; Accepted 6 December 2017; Published 17 January 2018

Academic Editor: Georgia Fousteri

Copyright © 2018 Nina Nielens et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. L. van Belle, K. T. Coppieters, and M. G. von Herrath, “Type 1 diabetes: etiology, immunology, and therapeutic strategies,” Physiological Reviews, vol. 91, no. 1, pp. 79–118, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. R. A. Watkins, C. Evans-Molina, J. S. Blum, and L. A. DiMeglio, “Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic review,” Translational Research, vol. 164, no. 2, pp. 110–121, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. P. A. Lysy, “Update on genetic determinants of type1 diabetes,” Journal of Molecular and Genetic Medicine, vol. 08, no. 03, pp. 126–133, 2014. View at Publisher · View at Google Scholar
  4. E. Akirav, J. A. Kushner, and K. C. Herold, “β-cell mass and type 1 diabetes: going, going, gone?” Diabetes, vol. 57, no. 11, pp. 2883–2888, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. I. M. Hramiak, J. Dupre, and D. T. Finegood, “Determinants of clinical remission in recent-onset IDDM,” Diabetes Care, vol. 16, no. 1, pp. 125–132, 1993. View at Publisher · View at Google Scholar
  6. H. Yki-Järvinen, R. A. DeFronzo, and V. A. Koivisto, “Normalization of insulin sensitivity in type I diabetic subjects by physical training during insulin pump therapy,” Diabetes Care, vol. 7, no. 6, pp. 520–527, 1984. View at Publisher · View at Google Scholar
  7. The Diabetes Control and Complications Trial group, “Hypoglycemia in the diabetes control and complications trial,” Diabetes, vol. 46, no. 2, pp. 271–286, 1997. View at Publisher · View at Google Scholar
  8. J. S. Sørensen, J. Johannesen, F. Pociot et al., “Residual β-cell function 3–6 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents,” Diabetes Care, vol. 36, no. 11, pp. 3454–3459, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Abdul-Rasoul, H. Habib, and M. Al-Khouly, ““The honeymoon phase” in children with type 1 diabetes mellitus: frequency, duration, and influential factors,” Pediatric Diabetes, vol. 7, no. 2, pp. 101–107, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Pecheur, T. Barrea, V. Vandooren, V. Beauloye, A. Robert, and P. A. Lysy, “Characteristics and determinants of partial remission in children with type 1 diabetes using the insulin-dose-adjusted A1C definition,” Journal of diabetes research, vol. 2014, Article ID 851378, 7 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Fonolleda, M. Murillo, and F. Vázquez, “Remission phase in paediatric type 1 diabetes: new understanding and emerging biomarkers,” Hormone Research in Paediatrics, vol. 88, no. 5, pp. 307–315, 2017. View at Publisher · View at Google Scholar
  12. R. L. Lundberg, K. R. Marino, A. Jasrotia et al., “Partial clinical remission in type 1 diabetes: a comparison of the accuracy of total daily dose of insulin of <0.3 units/kg/day to the gold standard insulin-dose adjusted hemoglobin A1c of ≤9 for the detection of partial clinical remission,” Journal of Pediatric Endocrinology and Metabolism, vol. 30, no. 8, pp. 823–830, 2017. View at Publisher · View at Google Scholar
  13. H. B. Mortensen, P. Hougaard, P. Swift et al., “New definition for the partial remission period in children and adolescents with type 1 diabetes,” Diabetes Care, vol. 32, no. 8, pp. 1384–1390, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. L. Max Andersen, P. Hougaard, S. Pörksen et al., “Partial remission definition: validation based on the insulin dose-adjusted HbA1c (IDAA1C) in 129 Danish children with new-onset type 1 diabetes,” Pediatric Diabetes, vol. 15, no. 7, pp. 469–476, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Hao, S. Gitelman, L. A. DiMeglio, D. Boulware, C. J. Greenbaum, and Type 1 Diabetes TrialNet Study Group, “Fall in C-peptide during first 4 years from diagnosis of type 1 diabetes: variable relation to age, HbA1c, and insulin dose,” Diabetes Care, vol. 39, no. 10, pp. 1664–1670, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Buckingham, P. Cheng, R. W. Beck et al., “CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes,” Diabetologia, vol. 58, no. 6, pp. 1167–1174, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Nagl, J. M. Hermann, M. Plamper et al., “Factors contributing to partial remission in type 1 diabetes: analysis based on the insulin dose-adjusted HbA1c in 3657 children and adolescents from Germany and Austria,” Pediatric Diabetes, vol. 18, no. 6, pp. 428–434, 2017. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Fukuda, A. Tanaka, Y. Tahara et al., “Correlation between minimal secretory capacity of pancreatic β-cells and stability of diabetic control,” Diabetes, vol. 37, no. 1, pp. 81–88, 1988. View at Publisher · View at Google Scholar
  19. G. Kramer, N. Kuniss, C. Kloos et al., “Principles and frequency of self-adjustment of insulin dose in people with diabetes mellitus type 1 and correlation with markers of metabolic control,” Diabetes Research and Clinical Practice, vol. 116, pp. 299–305, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. M. E. Craig, C. Jefferies, D. Dabelea, N. Balde, A. Seth, and K. C. Donaghue, “Definition, epidemiology, and classification of diabetes in children and adolescents,” Pediatric Diabetes, vol. 15, Supplement S20, pp. 4–17, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Roelants, R. Hauspie, and K. Hoppenbrouwers, “References for growth and pubertal development from birth to 21 years in Flanders, Belgium,” Annals of Human Biology, vol. 36, no. 6, pp. 680–694, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Forbes, R. A. Oram, A. Smith et al., “Validation of the BETA-2 score: an improved tool to estimate beta cell function after clinical islet transplantation using a single fasting blood sample,” American Journal of Transplantation, vol. 16, no. 9, pp. 2704–2713, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Dost, A. Herbst, K. Kintzel et al., “Shorter remission period in young versus older children with diabetes mellitus type 1,” Experimental and Clinical Endocrinology & Diabetes, vol. 115, no. 01, pp. 33–37, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. H. P. Chase, T. A. MacKenzie, J. Burdick et al., “Redefining the clinical remission period in children with type 1 diabetes,” Pediatric Diabetes, vol. 5, no. 1, pp. 16–19, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. O. M. Neylon, M. White, M. A. O´Connell, and F. J. Cameron, “Insulin-dose-adjusted HbA1c-defined partial remission phase in a paediatric population-when is the honeymoon over?” Diabetic Medicine, vol. 30, no. 5, pp. 627-628, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. J. J. Couper, M. J. Haller, A. G. Ziegler, M. Knip, J. Ludvigsson, and M. E. Craig, “Phases of type 1 diabetes in children and adolescents,” Pediatric Diabetes, vol. 15, Supplement S20, pp. 18–25, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. İ. Esen, F. Demirel, D. Tepe, and Ö. Kara, “Frequency of partial remission and related factors in children and adolescents diagnosed with type 1 diabetes mellitus,” International Journal of Diabetes in Developing Countries, vol. 35, no. 3, pp. 230–235, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. J. M. Lachin, I. Bebu, R. M. Bergenstal et al., “Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the diabetes control and complications trial,” Diabetes Care, vol. 40, no. 6, pp. 777–783, 2017. View at Publisher · View at Google Scholar
  29. I. B. Hirsch, “Glycemic variability and diabetes complications: does it matter? Of course it does!,” Diabetes care, vol. 38, no. 8, pp. 1610–1614, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Quagliaro, L. Piconi, and R. Assaloni, “Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation,” Diabetes, vol. 52, no. 11, pp. 2795–2804, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Monnier, E. Mas, C. Ginet et al., “Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes,” JAMA, vol. 295, no. 14, pp. 1681–1687, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Ceriello, K. Esposito, L. Piconi et al., “Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients,” Diabetes, vol. 57, no. 5, pp. 1349–1354, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. E. M. Horváth, R. Benkő, L. Kiss et al., “Rapid ‘glycaemic swings’ induce nitrosative stress, activate poly(ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus,” Diabetologia, vol. 52, no. 5, pp. 952–961, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. M. W. Steffes, S. Sibley, M. Jackson, and W. Thomas, “β-cell function and the development of diabetes-related complications in the diabetes control and complications trial,” Diabetes Care, vol. 26, no. 3, pp. 832–836, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Lind, A. M. Svensson, M. Kosiborod et al., “Glycemic control and excess mortality in type 1 diabetes,” New England Journal of Medicine, vol. 371, no. 21, pp. 1972–1982, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. E. B. Levitan, Y. Song, E. S. Ford, and S. Liu, “Is nondiabetic hyperglycemia a risk factor for cardiovascular disease?: a meta-analysis of prospective studies,” Archives of Internal Medicine, vol. 164, no. 19, pp. 2147–2155, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Sherr, V. W. Tamborlane, and D. Xing, “Achievement of target A1C levels with negligible hypoglycemia and low glucose variability in youth with short-term type 1 diabetes and residual β-cell function,” Diabetes Care, vol. 35, no. 4, pp. 817–820, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Saisho, “Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease?” International Journal of Molecular Sciences, vol. 15, no. 10, pp. 18381–18406, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Pozzilli, S. Manfrini, R. Buzzetti et al., “Glucose evaluation trial for remission (GETREM) in type 1 diabetes: a European multicentre study,” Diabetes Research and Clinical Practice, vol. 68, no. 3, pp. 258–264, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. S. A. Bowden, M. M. Duck, and R. P. Hoffman, “Young children (<5 yr) and adolescents (>12 yr) with type 1 diabetes mellitus have low rate of partial remission: diabetic ketoacidosis is an important risk factor,” Pediatric Diabetes, vol. 9, no. 3, Part 1, pp. 197–201, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Böber, B. Dündar, and A. Büyükgebiz, “Partial remission phase and metabolic control in type 1 diabetes mellitus in children and adolescents,” Journal of Pediatric Endocrinology and Metabolism, vol. 14, no. 4, pp. 435–441, 2001. View at Publisher · View at Google Scholar
  42. K. R. Marino, R. L. Lundberg, A. Jasrotia et al., “A predictive model for lack of partial clinical remission in new-onset pediatric type 1 diabetes,” PLoS One, vol. 12, no. 5, article e0176860, 2017. View at Publisher · View at Google Scholar
  43. V. M. Wagner, M. Grabert, and R. W. Holl, “Severe hypoglycaemia, metabolic control and diabetes management in children with type 1 diabetes in the decade after the diabetes control and complications trial – a large-scale multicentre study,” European Journal of Pediatrics, vol. 164, no. 2, pp. 73–79, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. W. Clarke, T. Jones, A. Rewers, D. Dunger, and G. J. Klingensmith, “Assessment and management of hypoglycemia in children and adolescents with diabetes,” Pediatric Diabetes, vol. 10, Supplement 12, pp. 134–145, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Johansen, B. Kanijo, S. Fredheim et al., “Prevalence and predictors of severe hypoglycemia in Danish children and adolescents with diabetes,” Pediatric Diabetes, vol. 16, no. 5, pp. 354–360, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Cengiz, D. Xing, J. C. Wong et al., “Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D exchange clinic registry,” Pediatric Diabetes, vol. 14, no. 6, pp. 447–454, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. E. S. Kilpatrick, A. S. Rigby, K. Goode, and S. L. Atkin, “Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes,” Diabetologia, vol. 50, no. 12, pp. 2553–2561, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. J. P. Palmer, G. A. Fleming, C. J. Greenbaum et al., “C-Peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function: report of an ADA workshop, 21–22 October 2001,” Diabetes, vol. 53, no. 1, pp. 250–264, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. E. B. Sochett, D. Daneman, C. Clarson, and R. M. Ehrlich, “Factors affecting and patterns of residual insulin secretion during the first year of type 1 (insulin-dependent) diabetes mellitus in children,” Diabetologia, vol. 30, no. 7, pp. 453–459, 1987. View at Publisher · View at Google Scholar · View at Scopus
  50. J. J. Couper, I. Hudson, G. A. Werther, G. L. Warne, J. M. Court, and L. C. Harrison, “Factors predicting residual β-cell function in the first year after diagnosis of childhood type 1 diabetes,” Diabetes Research and Clinical Practice, vol. 11, no. 1, pp. 9–16, 1991. View at Publisher · View at Google Scholar · View at Scopus
  51. A. G. Jones and A. T. Hattersley, “The clinical utility of C-peptide measurement in the care of patients with diabetes,” Diabetic Medicine, vol. 30, no. 7, pp. 803–817, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. N. Sherry, W. Hagopian, J. Ludvigsson et al., “Teplizumab for treatment of type 1 diabetes (protégé study): 1-year results from a randomised, placebo-controlled trial,” The Lancet, vol. 378, no. 9790, pp. 487–497, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. H. A. Keenan, J. K. Sun, J. Levine et al., “Residual insulin production and pancreatic β-cell turnover after 50 years of diabetes: Joslin medalist study,” Diabetes, vol. 59, no. 11, pp. 2846–2853, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. E. A. Ryan, B. W. Paty, and P. A. Senior, “β-Score: an assessment of β-cell function after islet transplantation,” Diabetes Care, vol. 28, no. 2, pp. 343–347, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. M. C. Vantyghem, V. Raverdy, and A. S. Balavoine, “Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (β-score greater than 7) is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (β-score greater than 3),” The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 11, pp. E2078–E2083, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. F. B. Barton, M. R. Rickels, R. Alejandro et al., “Improvement in outcomes of clinical islet transplantation: 1999-2010,” Diabetes Care, vol. 35, no. 7, pp. 1436–1445, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. D. J. Holmes-Walker, J. E. Gunton, W. Hawthorne et al., “Islet transplantation provides superior glycemic control with less hypoglycemia compared with continuous subcutaneous insulin infusion or multiple daily insulin injections,” Transplantation, vol. 101, no. 6, pp. 1268–1275, 2017. View at Publisher · View at Google Scholar · View at Scopus